Our Strategy

Chapter 02

Business andGlobal Expansion

Therapeutic Solutions Business

Strategy, Progress, and Future Measures by Area

TherapeuticSolutions BusinessBusiness Foundations

We aim to improve patient outcomesby elevating the standard ofcare through minimally invasive
solutions in targeted disease states.”

StrategyHighlights	Deliver above-market, profitable growth throughclinically and economically differentiated solutions	Focus on disease states in specialties where we canhave a market-leading impact	Operate efficiently from inception to sale while
ensuring utmost quality and reliability	Leverage business development to accelerate
expansion of the product portfolio through external
partnerships, licensing and M&A	Exceeded growth and operating profit targets, delivering positive above
market growth across overall TSD portfolio	Key therapeutic areas strengthened through series of deals andpartnerships	Further strengthened our position as a global MedTech company byestablishing Olympus Innovation Ventures to invest in pioneering startups
with innovative technologies that improve clinical outcomes, reduce
healthcare costs, and enhance the quality of life for patients

Focusing on Three Therapeutic Areas
To accelerate growth in Therapeutic Solutions Business and enhance our value in minimally invasive treatment,
we will focus on category leadership across three therapeutic areas
Strategy

Gabriela Kaynor (left), Seiji Kuramoto (right)

GI-Endotherapy
Expanding clinically and economicallydifferentiated product portfolio acrossall key categories, including ERCP*2, ESD*3,
metal stents, and hemostasis devices

Co-heads of Therapeutic Solutions DivisionResults(¥ Billion)

FY2023 Sales Composition(%)

Company Strategy Target500

GI-Endotherapy

Revenue CAGR > 5 %Approx. 30%

4004030030Main Products

20020GI-Endotherapy

100100Urology

Respiratory

Others

5020241(Forecast) *Approx. 35%

Urology

Approx. 15%

Respiratory

Approx. 20%Others

20222023

Revenue

275.6

318.2329.0(¥ billion)

 peratingO
Margin

22.1

20.0

17.0

(%)

Respiratory
ERCP*2 andultrasound products

Flexible
cystoscopes

Bronchoscopes

Energydevices

EMR*4 andESD*3 products

Resection
electrodes

Single-use
aspiration needles

ENTproducts

Note: F rom FY2023, gynecology, which were classified in the othersof Therapeutic Solutions Business, have been included in theurology segment of Therapeutic Solutions Business.
Accordingly, we restated figures for FY2022.

Increased procedures driven by aging population and therise of chronic diseaseIntensifying cost pressures on health systems continues todrive focus on both clinical and economic value and require
new care models focused on improved patient outcomes

Olympus Integrated Report 2023	#1 in reusable ureteroscopes—launch of single-use ureteroscope will
expand clinician options	Portfolio of Laser and Ultrasonic lithotripsy systems enables share capture	#1 in Thulium Fiber Laser lithotripsy systems (Soltive SuperPulsed LaserSystem) and fibers	Existing market leading position in cystoscopes, resectoscopes, andresection electrodes	PLASMA+ system designed to shorter procedure times	Expanded reimbursement for differentiated MIS BPH device which
provides better clinical outcomes and elevates the standard of care*7

Delivering market-leading solutions
designed to improve care and prognosis oflung cancer patients through accurate,early diagnosis and staging	Leading market position of >70% share*5 in pulmonary bronchoscopes,endotherapy, EBUS scopes and EBUS TBNA needles	Slim EBUS will enable access to suspicious lesions beyond the central /middle lung regions

Other Therapeutic Areas

Operating Environment

52

Becoming the global leader in BPH, stone
management, and bladder cancer throughcustomer-focused innovation andcompelling clinical differentiation	~20% global share*5 with double-digit growth in our ESD*3/EMR*4,ENDOCUFF VISION, EndoClot portfolios	Acquisition*6 of broad metal stent portfolio will significantly accelerate ourglobal position and options in biliary tract, esophagus, colon, andduodenum treatments	Single-use cholangioscope will enhance clinician optionality

0(FY)*1 Forecast as of August 9, 2023

UrologyHighlights

 ngoing shift from open surgeries to minimally invasive treatments
O
that improve patient outcomes and optimize total cost of care
Changes in demand for care with a shift to lower cost caresettings (from inpatient to outpatient) enabled by less-invasive
techniques

Strategy	Expand energy solutions portfolio	Protect and grow laryngology and rhinology
businesses through investing in solutions that follow
market shifts toward minimally invasive procedures
across the continuum of care

Progress and Future Measures	Expanding launch of POWERSEAL, an advanced bipolar surgical energy
device with strong and efficient sealing of vessels. Further strengthening
the energy device portfolio with THUNDERBEAT and SONICBEAT	Launched CELERIS single-use microdebrider, which is designed for ENTs.
CELERIS eliminates staff disruption and helps to improve patient outcomesby reducing infection risk

*2	Endoscopic Retrograde Cholangio Pancreatography*3 Endoscopic Submucosal Dissection*4 Endoscopic Mucosal Resection*5	Addressable market, growth and Olympus position based upon publicly available data and Olympus
research, and pertains to data for the U.S., Germany, UK, Italy, France, Spain, Japan and China.

*6	Acquisition of Taewoong medical Co., Ltd,: Closure pending*7	iTind procedure does not require a permanent implant and preserves sexual function
and continence, while reducing the need for a post procedure catheter. Procedure canbe done in the MD office setting.

53